Most people respond to a breakup with ice cream. A top CVS Health executive responded with a $2 million CVS insider stock purchase, two days after the company said it plans to break itself in two. And in a market full of selling, this is the kind of move people notice.
Prem Shah, CVS’s Executive Vice President and Group President, bought 23,855 shares on the open market on Nov. 6, according to a Form 4 filed with the SEC. He paid $83.895 a share, which comes to about $2.0 million. The filing landed at 4:42 p.m. ET on Friday, so Monday is the first regular trading session where the market can react to it. For a look at what else is moving that day, see our rundown of a packed Monday on Wall Street.
What the CVS Form 4 purchase shows
This was a real buy, not a stock award. The Form 4 uses transaction code “P,” which means an open-market purchase with his own cash. After the trade, Shah holds 88,516 shares directly.
That is roughly 37% more than he held the day before. Shah oversees Pharmacy Services, Pharmacy & Consumer Wellness and Health Care Delivery, according to his CVS bio. He has been with the company since 2013.
Here’s the thing: insiders sell stock for a hundred reasons, but they buy it for one. They think it’s worth more than the price on the screen. That said, one CVS insider stock purchase is a signal, not a pattern, and the filing doesn’t say why he bought (so any mind-reading is on the house).
The breakup behind this CVS executive stock buy
On Nov. 4, CVS announced it intends to separate into two independent, publicly traded companies. The transaction is meant to be tax-free for federal income tax purposes, per its latest quarterly filing. The target is the first half of 2028, CNBC reports.
One company, which would keep the CVS Health name, would hold Aetna, CVS Caremark, CVS Specialty, Oak Street Health and Signify Health. The other, CVS Pharmacy, would take roughly 9,000 stores, mail pharmacy, MinuteClinic and the Health100 technology business. Existing shareholders would own stock in both.
The split would undo the $78 billion Aetna deal from 2018. CVS flirted with a breakup in 2024 and walked away. This time it’s going through with it. It also follows a messy stretch for the company, including the Omnicare sale to GenieRx.
Wall Street did not love it, but CVS insider buying followed
Shares fell roughly 10% to 12.5% on the announcement, depending on which outlet’s math you trust. One analysis has the stock dropping $11.45 to close at $79.96. Shah’s purchase price of $83.895 was above that close, so he paid more than the post-announcement low.
Meanwhile, the company also raised its 2026 adjusted earnings guidance to at least $8.20 a share. CEO David Joyner has said regulators were not the reason for the split, Healthcare Dive reports.
Why this CVS insider stock purchase stands out
Open-market insider buys at CVS have been rare. Quiver Quantitative reports this is the first one since June 2025, when director Guy Sansone bought 1,570 shares. That 17-month gap is Quiver’s count, and we couldn’t match it against a full Form 4 history. Treat it as a good estimate rather than gospel.
So does a $2 million vote of confidence mean the stock is a steal? Not necessarily. Executives can be wrong, and a split that won’t close for roughly 18 months leaves plenty of room for surprises. Pricing pressure is one example, as our look at CVS Caremark’s regulatory heat shows.
Still, the next thing to watch is simple: do other CVS executives or directors follow Shah in with their own checkbooks? One buy is a headline. Several would be a story.
